Regulatory milestones

Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.56 (12%) to $5.05 last week after the U.K.'s NICE issued draft guidance recommending Iluvien fluocinolone acetonide intravitreal implant for chronic diabetic macular edema (DME) patients considered insufficiently responsive to available therapies and who have had their natural lens replaced with an intraocular lens.

-- Sydney Blankers